Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02869789 · ClinicalTrials.gov registry record · Phase 4
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
A Phase 4 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,041
- Enrollment target
NCT02869789: Completed Phase 4 study, sponsored by Bristol-Myers Squibb.
NCT02869789 is a Phase 4 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,041 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (101% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02869789, a Phase 4 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,041 participants
- Enrollment target
Study Summary
A study to evaluate the safety of Nivolumab given in combination with Ipilimumab in patients with advanced cancers. The initial group will enroll patients with newly diagnosed Stage 4 or non-small cell lung cancer that has come back.
Primary Outcome
Drug related AEs are those events with relationship to study drug. If the relationship to study drug is missing, the AE will be considered as drug-related. The select AEs of interest are the following: Pulmonary, Renal, Gastrointestinal, Hepatic, Skin, Endocrine, and hypersensitivity/infusion reaction events. AEs are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4. Grade 3= Prolonged severe reaction Grade 4= Life threatening Gr
Interventions
- DRUG Nivolumab in combination with Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,041 participants |
| Start Date | 2016-10-05 |
| Est. Completion | 2022-05-13 |
| Phase | Phase 4 |
What the finished NCT02869789 record still lists
NCT02869789 is an interventional study that assigns participants to a tested intervention. Its 1,041 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (101% higher).
The record links to 0 conditions, and to 1 intervention - of which Nivolumab in combination with Ipilimumab is the first listed.
NCT02869789 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02869789 about?
NCT02869789 is a clinical study titled "An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers". A study to evaluate the safety of Nivolumab given in combination with Ipilimumab in patients with advanced cancers. The initial group will enroll patients with newly diagnosed Stage 4 or non-small cell lung cancer that has come back.
What is the current status of trial NCT02869789?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,041 participants. The study started on 2016-10-05. Estimated completion is 2022-05-13.
What interventions are being tested in trial NCT02869789?
The interventions under investigation include: Nivolumab in combination with Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT02869789?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02869789's enrollment target sits among peer trials
1,041 66th of 2000 higher than 1,935 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04685616 · 1,042 participants · Phase 3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
- NCT05219110 · 1,040 participants · NA
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
- NCT06564948 · 1,040 participants · NA
Treatment for Individuals Interacting with the Criminal Justice System
- NCT06661720 · 1,040 participants · Phase 3
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI